ImmunityBio (NASDAQ:IBRX) Announces Earnings Results
ImmunityBio (NASDAQ:IBRX – Get Free Report) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of…
ImmunityBio (NASDAQ:IBRX – Get Free Report) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of…
ImmunityBio (NASDAQ:IBRX) Announces Earnings Results
ImmunityBio (NASDAQ:IBRX – Get Free Report) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of…
news-area.com
November 10, 2026 at 12:58 AM
ImmunityBio (NASDAQ:IBRX) Announces Earnings Results
ImmunityBio (NASDAQ:IBRX – Get Free Report) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of…
ImmunityBio (NASDAQ:IBRX – Get Free Report) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of…
ImmunityBio Says ANKTIVA Plus BCG Met Bladder Cancer Trial Goal; FDA Filing Planned by Year End
Northwalker / CC0 ImmunityBio said in Culver City, California, on November 9 that ANKTIVA combined with BCG met the primary efficacy endpoint in Cohort A of its randomized QUILT-2.005 bladder cancer…
Northwalker / CC0 ImmunityBio said in Culver City, California, on November 9 that ANKTIVA combined with BCG met the primary efficacy endpoint in Cohort A of its randomized QUILT-2.005 bladder cancer…
ImmunityBio Says ANKTIVA Plus BCG Met Bladder Cancer Trial Goal; FDA Filing Planned by Year End
Northwalker / CC0 ImmunityBio said in Culver City, California, on November 9 that ANKTIVA combined with BCG met the primary efficacy endpoint in Cohort A of its randomized QUILT-2.005 bladder cancer trial. The company reported a statistically significant improvement over BCG alone in patients with carcinoma in situ, with or without papillary tumors, but did not release the numerical results needed to judge the size of that benefit.
jbiznews.com
November 9, 2026 at 1:05 PM
ImmunityBio Says ANKTIVA Plus BCG Met Bladder Cancer Trial Goal; FDA Filing Planned by Year End
Northwalker / CC0 ImmunityBio said in Culver City, California, on November 9 that ANKTIVA combined with BCG met the primary efficacy endpoint in Cohort A of its randomized QUILT-2.005 bladder cancer…
Northwalker / CC0 ImmunityBio said in Culver City, California, on November 9 that ANKTIVA combined with BCG met the primary efficacy endpoint in Cohort A of its randomized QUILT-2.005 bladder cancer…
#IBRX ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized Q…
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-anktiva-plus-bcg-meets-primary-endpoint-in-912nnt005svb.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-anktiva-plus-bcg-meets-primary-endpoint-in-912nnt005svb.html?utm_source=stocktitan-bluesky&utm_medium=social
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 9, 2026 at 11:30 AM
#IBRX ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized Q…
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-anktiva-plus-bcg-meets-primary-endpoint-in-912nnt005svb.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-anktiva-plus-bcg-meets-primary-endpoint-in-912nnt005svb.html?utm_source=stocktitan-bluesky&utm_medium=social
💊 Valneva reported positive Phase 2 results for Shigella.
🏛️ Retiring Nancy Pelosi filed a final stock trade.
📊 Demetra Holdings bought 4,080 shares at €1.32 each.
📉 ImmunityBio stock fell despite Q3 revenue misses.
🏛️ Retiring Nancy Pelosi filed a final stock trade.
📊 Demetra Holdings bought 4,080 shares at €1.32 each.
📉 ImmunityBio stock fell despite Q3 revenue misses.
November 9, 2026 at 10:15 PM
💊 Valneva reported positive Phase 2 results for Shigella.
🏛️ Retiring Nancy Pelosi filed a final stock trade.
📊 Demetra Holdings bought 4,080 shares at €1.32 each.
📉 ImmunityBio stock fell despite Q3 revenue misses.
🏛️ Retiring Nancy Pelosi filed a final stock trade.
📊 Demetra Holdings bought 4,080 shares at €1.32 each.
📉 ImmunityBio stock fell despite Q3 revenue misses.
#IBRX ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Inv…
https://www.stocktitan.net/news/IBRX/immunity-bio-and-rafa-announce-israeli-ministry-of-health-approval-yik06c87uys6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-and-rafa-announce-israeli-ministry-of-health-approval-yik06c87uys6.html?utm_source=stocktitan-bluesky&utm_medium=social
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 9, 2026 at 12:00 PM
#IBRX ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Inv…
https://www.stocktitan.net/news/IBRX/immunity-bio-and-rafa-announce-israeli-ministry-of-health-approval-yik06c87uys6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-and-rafa-announce-israeli-ministry-of-health-approval-yik06c87uys6.html?utm_source=stocktitan-bluesky&utm_medium=social
ImmunityBio $IBRX reported Q3 2026 Adj EPS of -$0.09, missing the -$0.06 estimate by 53.3%. Revenue of $48.8M missed the $59.5M estimate by 18.0%.
https://fundspec.ai/s/IBRX/earnings
Watchlists that sync across every device you own.
https://fundspec.ai/s/IBRX/earnings
Watchlists that sync across every device you own.
November 9, 2026 at 1:05 PM
ImmunityBio $IBRX reported Q3 2026 Adj EPS of -$0.09, missing the -$0.06 estimate by 53.3%. Revenue of $48.8M missed the $59.5M estimate by 18.0%.
https://fundspec.ai/s/IBRX/earnings
Watchlists that sync across every device you own.
https://fundspec.ai/s/IBRX/earnings
Watchlists that sync across every device you own.
Unusual options activity in #$IBRX, mostly calls. That's call money going into a stock that's sitting at a one-month low.
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#optionsflow #stocks #optionstrading #trading
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#optionsflow #stocks #optionstrading #trading
ImmunityBio (IBRX) Institutional Flow at 10:46 AM: 78% of the Options Money in Calls
ImmunityBio (IBRX) at 10:46 AM ET: options money leaning to calls. The latest institutional flow, the biggest unusual bets and what would confirm or invalidate the move.
globaltradersacademy.com
November 9, 2026 at 4:33 PM
Unusual options activity in #$IBRX, mostly calls. That's call money going into a stock that's sitting at a one-month low.
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#optionsflow #stocks #optionstrading #trading
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#optionsflow #stocks #optionstrading #trading
#IBRX ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up…
https://www.stocktitan.net/news/IBRX/immunity-bio-reports-label-expansion-and-additional-global-approval-0iupwt9hwj56.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-reports-label-expansion-and-additional-global-approval-0iupwt9hwj56.html?utm_source=stocktitan-bluesky&utm_medium=social
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 9, 2026 at 12:30 PM
#IBRX ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up…
https://www.stocktitan.net/news/IBRX/immunity-bio-reports-label-expansion-and-additional-global-approval-0iupwt9hwj56.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-reports-label-expansion-and-additional-global-approval-0iupwt9hwj56.html?utm_source=stocktitan-bluesky&utm_medium=social
ImmunityBio (#$IBRX) Earnings Nov. 10: Options Market Bets on a 13% Move. Options imply a 12.7% move for IBRX after it reports on Tuesday, Nov. 10.
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#stocks #trading
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#stocks #trading
ImmunityBio (IBRX) Earnings Nov. 10: Options Market Bets on a 13% Move
IBRX reports earnings soon, and options traders are bracing for a big move. See what the options market is pricing in and which way the money leans.
globaltradersacademy.com
November 9, 2026 at 12:33 PM
ImmunityBio (#$IBRX) Earnings Nov. 10: Options Market Bets on a 13% Move. Options imply a 12.7% move for IBRX after it reports on Tuesday, Nov. 10.
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#stocks #trading
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.
Read the full article for the full details.
#stocks #trading
#Healthcare ImmunityBio announced on November 9 that ANKTIVA (nogapendekin alfa inbakicept-pmln/N-803) in combination with BCG met the primary endpoint in the final analysis of Cohort A of its randomized, controlled QUILT-2.005 trial, which enrolled 366 patients with BCG-naive, ... Continue reading
November 9, 2026 at 1:55 PM
#Healthcare ImmunityBio announced on November 9 that ANKTIVA (nogapendekin alfa inbakicept-pmln/N-803) in combination with BCG met the primary endpoint in the final analysis of Cohort A of its randomized, controlled QUILT-2.005 trial, which enrolled 366 patients with BCG-naive, ... Continue reading
#Healthcare ImmunityBio announced on November 9 that ANKTIVA (nogapendekin alfa inbakicept-pmln/N-803) in combination with BCG met the primary endpoint in the final analysis of Cohort A of its randomized, controlled QUILT-2.005 trial, which enrolled 366 patients with BCG-naive, ... Continue reading
November 9, 2026 at 12:40 PM
#Healthcare ImmunityBio announced on November 9 that ANKTIVA (nogapendekin alfa inbakicept-pmln/N-803) in combination with BCG met the primary endpoint in the final analysis of Cohort A of its randomized, controlled QUILT-2.005 trial, which enrolled 366 patients with BCG-naive, ... Continue reading
🚨 $IBRX
On November 9, 2026, ImmunityBio, Inc. issued a press release announcing that ANKTIVA ® plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial . The full text of the Company’s press releas...
On November 9, 2026, ImmunityBio, Inc. issued a press release announcing that ANKTIVA ® plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial . The full text of the Company’s press releas...
SEC Filing: IBRX
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 11:34 AM
🚨 $IBRX
On November 9, 2026, ImmunityBio, Inc. issued a press release announcing that ANKTIVA ® plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial . The full text of the Company’s press releas...
On November 9, 2026, ImmunityBio, Inc. issued a press release announcing that ANKTIVA ® plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial . The full text of the Company’s press releas...
🚨 $IBRX
On November 9, 2026, ImmunityBio, Inc. issued a press release providing a business update and announcing its financial results for the three and nine months ended September 30, 2026, and its financial position as of September 30, 2026. The full text of the Company’s press release is furni...
On November 9, 2026, ImmunityBio, Inc. issued a press release providing a business update and announcing its financial results for the three and nine months ended September 30, 2026, and its financial position as of September 30, 2026. The full text of the Company’s press release is furni...
SEC Filing: IBRX
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 12:40 PM
🚨 $IBRX
On November 9, 2026, ImmunityBio, Inc. issued a press release providing a business update and announcing its financial results for the three and nine months ended September 30, 2026, and its financial position as of September 30, 2026. The full text of the Company’s press release is furni...
On November 9, 2026, ImmunityBio, Inc. issued a press release providing a business update and announcing its financial results for the three and nine months ended September 30, 2026, and its financial position as of September 30, 2026. The full text of the Company’s press release is furni...
Patrick Soon-Shiong renewed his “NantX coming soon” teaser after a $6.3 billion Binance theft, spotlighting a separate financial-services venture. ImmunityBio […]
ImmunityBio founder touts sepsis trials, NantX after Binance theft
Patrick Soon-Shiong renewed his “NantX coming soon” teaser after a $6.3 billion Binance theft, spotlighting a separate financial-services venture. ImmunityBio […]
bitnewsbot.com
November 3, 2026 at 7:34 AM
Patrick Soon-Shiong renewed his “NantX coming soon” teaser after a $6.3 billion Binance theft, spotlighting a separate financial-services venture. ImmunityBio […]
$IBRX ImmunityBio Directors Sell $1.1M Before Key Bladder Data
Directors Sell $1.1M Before Bladder Trial Data
Directors at ImmunityBio sold $1.1M at 32% above current prices just weeks before November trial data. What their insider timing reveals about cash burn.
www.basisreport.com
November 3, 2026 at 2:20 PM
$IBRX ImmunityBio Directors Sell $1.1M Before Key Bladder Data
#IBRX ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive B…
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-first-patients-in-europe-treated-with-anktiva-89m5tteutn1c.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-first-patients-in-europe-treated-with-anktiva-89m5tteutn1c.html?utm_source=stocktitan-bluesky&utm_medium=social
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 1:00 PM
#IBRX ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive B…
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-first-patients-in-europe-treated-with-anktiva-89m5tteutn1c.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/IBRX/immunity-bio-announces-first-patients-in-europe-treated-with-anktiva-89m5tteutn1c.html?utm_source=stocktitan-bluesky&utm_medium=social
#$IBRX weekly close $8.29 (+0.9% w/w), below SMA50 $8.71 / above SMA200 $7.90, RSI 43.8. Support $7.75, resistance $10.82. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/immunitybio-...
New hub updated: www.merlintrader.com/immunitybio-...
October 31, 2026 at 12:03 PM
#$IBRX weekly close $8.29 (+0.9% w/w), below SMA50 $8.71 / above SMA200 $7.90, RSI 43.8. Support $7.75, resistance $10.82. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/immunitybio-...
New hub updated: www.merlintrader.com/immunitybio-...
#$IBRX weekly close $8.29 (+0.9% w/w), below SMA50 $8.71 / above SMA200 $7.90, RSI 43.8. Support $7.75, resistance $10.82. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/immunitybio-...
New hub updated: www.merlintrader.com/immunitybio-...
October 31, 2026 at 12:03 PM
#$IBRX weekly close $8.29 (+0.9% w/w), below SMA50 $8.71 / above SMA200 $7.90, RSI 43.8. Support $7.75, resistance $10.82. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/immunitybio-...
New hub updated: www.merlintrader.com/immunitybio-...
$IBRX QUILT-2.005 topline guided to November. Oct 21: database lock for 366 patients; sBLA planned for Q4 (procedural, not efficacy). Rebuilt hub with the 50-page PDF report. Not investment advice.
https://www.merlintrader.com/immunitybio-inc-nasdaq-ibrx-stock-hub/?v=snello
https://www.merlintrader.com/immunitybio-inc-nasdaq-ibrx-stock-hub/?v=snello
IBRX Stock: ImmunityBio News, ANKTIVA & QUILT Data
ImmunityBio stock news: ANKTIVA expands into papillary-only NMIBC; QUILT-2.005 topline is expected in November, with sales, cash and dilution in focus.
www.merlintrader.com
October 30, 2026 at 12:47 AM
$IBRX QUILT-2.005 topline guided to November. Oct 21: database lock for 366 patients; sBLA planned for Q4 (procedural, not efficacy). Rebuilt hub with the 50-page PDF report. Not investment advice.
https://www.merlintrader.com/immunitybio-inc-nasdaq-ibrx-stock-hub/?v=snello
https://www.merlintrader.com/immunitybio-inc-nasdaq-ibrx-stock-hub/?v=snello